請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72816
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林泰元(Thai-Yen Ling) | |
dc.contributor.author | Ching-Fu Weng | en |
dc.contributor.author | 翁菁甫 | zh_TW |
dc.date.accessioned | 2021-06-17T07:07:01Z | - |
dc.date.available | 2021-02-23 | |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-01-07 | |
dc.identifier.citation | 1. Wang BY, Huang JY, Cheng CY, Lin CH, Ko J, Liaw YP. Lung cancer and prognosis in taiwan: a population-based cancer registry. J Thorac Oncol. 2013;8(9):1128-35.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. 4. Yang X, Lin D. [Changes of 2015 WHO Histological Classification of Lung Cancer and the Clinical Significance]. Zhongguo Fei Ai Za Zhi. 2016;19(6):332-6. 5. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59(8):790-800. 6. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-54. 7. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016;11(10):1653-71. 8. Planchard D, Besse B. Lung cancer in never-smokers. Eur Respir J. 2015;45(5):1214-7. 9. Toh CK, Wong EH, Lim WT, Leong SS, Fong KW, Wee J, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126(6):1750-6. 10. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41. 11. Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett. 2014;345(2):174-81. 12. Stohr K. Influenza--WHO cares. Lancet Infect Dis. 2002;2(9):517. 13. Baskerville A, Thomas G, Wood M, Harris WJ. Histology and ultrastructure of metaplasia of alveolar epithelium following infection of mice and hamsters with influenza virus. Br J Exp Pathol. 1974;55(2):130-7. 14. Kotin P, Wiseley DV. Production of Lung Cancer in Mice by Inhalation Exposure to Influenza Virus and Aerosols of Hydrocarbons. Prog Exp Tumor Res. 1963;3:186-215. 15. Shimkin MB, Stoner GD. Lung tumors in mice: application to carcinogenesis bioassay. Adv Cancer Res. 1975;21:1-58. 16. Gonzalez-Mariscal L, Garay E, Lechuga S. Virus interaction with the apical junctional complex. Front Biosci (Landmark Ed). 2009;14:731-68. 17. Spear PG. Viral interactions with receptors in cell junctions and effects on junctional stability. Dev Cell. 2002;3(4):462-4. 18. Arnberg N. Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci. 2012;33(8):442-8. 19. Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020;12(559). 20. Patzke C, Max KE, Behlke J, Schreiber J, Schmidt H, Dorner AA, et al. The coxsackievirus-adenovirus receptor reveals complex homophilic and heterophilic interactions on neural cells. J Neurosci. 2010;30(8):2897-910. 21. Zhang X, Fang B, Mohan R, Chang JY. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol.2012;105(2):250-7. 22. Gu SY, Ho CC, Huang YK, Chen HW, Wang YC, Kuo CY, et al. Acquisition of tumorigenic potential and enhancement of angiogenesis in pulmonary stem/progenitor cells through Oct-4 hyperexpression. Oncotarget. 2016;7(12):13917-31. 23. Wunder T, Schmid K, Wicklein D, Groitl P, Dobner T, Lange T, et al. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection. Cancer Gene Ther. 2013;20(1):25-32. 24. Wang Y, Wang S, Bao Y, Ni C, Guan N, Zhao J, et al. Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers. J Mol Histol. 2006;37(3-4):153-60. 25. Cooper F, Overmiller AM, Loder A, Brennan-Crispi DM, McGuinn KP, Marous MR, et al. Enhancement of Cutaneous Wound Healing by Dsg2 Augmentation of uPAR Secretion. J Invest Dermatol. 2018;138(11):2470-9. 26. Nava P, Laukoetter MG, Hopkins AM, Laur O, Gerner-Smidt K, Green KJ, et al. Desmoglein-2: a novel regulator of apoptosis in the intestinal epithelium. Mol Biol Cell. 2007;18(11):4565-78. 27. Stasiak AC, Stehle T. Human adenovirus binding to host cell receptors: a structural view. Med Microbiol Immunol. 2020;209(3):325-33. 28. Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel). 2018;10(8). 29. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(9):1496-504. 30. Hung JJ, Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC, et al. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32(22):2357-64. 31. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34(8):1155-62. 32. Yeh YC, Wu YC, Chen CY, Wang LS, Hsu WH, Chou TY. Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: histopathological categories for prognosis prediction. J Clin Pathol. 2012;65(10):910-8. 33. Zhang J, Wu J, Tan Q, Zhu L, Gao W. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol. 2013;8(9):1196-202. 34. Zhang Y, Sun Y, Xiang J, Zhang Y, Hu H, Chen H. A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer. J Thorac Cardiovasc Surg. 2014;148(4):1193-9. 35. Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020. 36. Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, et al. The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. J Thorac Oncol. 2014;9(5):654-63. 37. Da Cruz V, Yvorel V, Casteillo F, Tissot C, Luchez A, Bayle-Bleuez S, et al. Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma. Lung Cancer. 2020;147:77-82. 38. Campos-Parra AD, Aviles A, Contreras-Reyes S, Rojas-Marin CE, Sanchez-Reyes R, Borbolla-Escoboza RJ, et al. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur Respir J. 2014;43(5):1439-47. 39. Casteillo F, Guy JB, Dal-Col P, Karpathiou G, Pommier B, Bayle-Bleuez S, et al. Pathologic Subtypes of Lung Adenocarcinoma Brain Metastasis Is a Strong Predictor of Survival After Resection. Am J Surg Pathol. 2018;42(12):1701-7. 40. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137(5):668-84. 41. Gao S, Stein S, Petre EN, Shady W, Durack JC, Ridge C, et al. Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. Cardiovasc Intervent Radiol. 2018;41(2):253-9. 42. Riely GJ, Travis WD. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? Eur Respir J. 2014;43(5):1240-2. 43. Kim TH, Buonocore D, Petre EN, Durack JC, Maybody M, Johnston RP, et al. Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma. Ann Thorac Surg. 2019;108(2):392-8. 44. Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, et al. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;97(1):138-45. 45. Matsuzawa R, Kirita K, Kuwata T, Umemura S, Matsumoto S, Fujii S, et al. Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma. Lung Cancer. 2016;94:1-6. 46. Chao L, Yi-Sheng H, Yu C, Li-Xu Y, Xin-Lan L, Dong-Lan L, et al. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients. Lung Cancer. 2014;86(2):164-9. 47. Swanton C, Govindan R. Clinical Implications of Genomic Discoveries in Lung Cancer. N Engl J Med. 2016;374(19):1864-73. 48. Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J. 2014;43(3):872-83. 49. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg. 2014;98(2):453-8. 50. Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J Formos Med Assoc. 2016;115(12):1076-88. 51. Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45(3):291-6. 52. Hsing AW, Ioannidis JP. Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175(9):1527-9. 53. Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009;15(8):659-68. 54. Desai RJ, Glynn RJ, Wang S, Gagne JJ. Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. Am J Epidemiol. 2016;183(10):949-57. 55. Mornex JF, Thivolet F, De las Heras M, Leroux C. Pathology of human bronchioloalveolar carcinoma and its relationship to the ovine disease. Curr Top Microbiol Immunol. 2003;275:225-48. 56. Brouchet L, Valmary S, Dahan M, Didier A, Galateau-Salle F, Brousset P, et al. Detection of oncogenic virus genomes and gene products in lung carcinoma. Br J Cancer. 2005;92(4):743-6. 57. Castro CY, Ostrowski ML, Barrios R, Green LK, Popper HH, Powell S, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol. 2001;32(8):863-72. 58. Giuliani L, Jaxmar T, Casadio C, Gariglio M, Manna A, D'Antonio D, et al. Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer. 2007;57(3):273-81. 59. Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G. The role of human papilloma virus in lung cancer: a review of the evidence. Am J Med Sci. 2009;338(1):64-7. 60. Sion-Vardy N, Lasarov I, Delgado B, Gopas J, Benharroch D, Ariad S. Measles virus: evidence for association with lung cancer. Exp Lung Res. 2009;35(8):701-12. 61. Chaturvedi AK, Gaydos CA, Agreda P, Holden JP, Chatterjee N, Goedert JJ, et al. Chlamydia pneumoniae infection and risk for lung cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1498-505. 62. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32-7. 63. Hosgood HD, 3rd, Boffetta P, Greenland S, Lee YC, McLaughlin J, Seow A, et al. In-home coal and wood use and lung cancer risk: a pooled analysis of the International Lung Cancer Consortium. Environ Health Perspect. 2010;118(12):1743-7. 64. Lipsett M, Campleman S. Occupational exposure to diesel exhaust and lung cancer: a meta-analysis. Am J Public Health. 1999;89(7):1009-17. 65. Steenland K, Loomis D, Shy C, Simonsen N. Review of occupational lung carcinogens. Am J Ind Med. 1996;29(5):474-90. 66. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5-8. 67. McDougall JK. 'Hit and run' transformation leading to carcinogenesis. Dev Biol (Basel). 2001;106:77-82; discussion -3, 143-60. 68. Ashley DJ. The two 'hit' and multiple 'hit' theories of carcinogenesis. Br J Cancer.1969;23(2):313-28. 69. Olsen SJ, Kittikraisak W, Fernandez S, Suntarattiwong P, Chotpitayasunondh T. Challenges with new rapid influenza diagnostic tests. Pediatr Infect Dis J. 2014;33(1):117-8. 70. Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ. 2012;345:e8076. 71. Ung MH, MacKenzie TA, Onega TL, Amos CI, Cheng C. Statins associate with improved mortality among patients with certain histological subtypes of lung cancer. Lung Cancer. 2018;126:89-96. 72. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28-35. 73. Reeh M, Bockhorn M, Gorgens D, Vieth M, Hoffmann T, Simon R, et al. Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109(7):1848-58. 74. Wang B, Chen G, Li F, Zhou J, Lu Y, Ma D. Inhibitory effect of coxsackie adenovirus receptor on invasion and metastasis phenotype of ovarian cancer cell line SKOV3. J Huazhong Univ Sci Technolog Med Sci. 2005;25(1):85-7, 93. 75. Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM. Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci U S A. 2003;100(4):1943-8. 76. Qin M, Escuadro B, Dohadwala M, Sharma S, Batra RK. A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res. 2004;64(18):6377-80. 77. Veena MS, Qin M, Andersson A, Sharma S, Batra RK. CAR mediates efficient tumor engraftment of mesenchymal type lung cancer cells. Lab Invest. 2009;89(8):875-86. 78. Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, et al. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget. 2016;7(29):46492-508. 79. Kurzen H, Munzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol. 2003;30(10):621-30. 80. Biedermann K, Vogelsang H, Becker I, Plaschke S, Siewert JR, Hofler H, et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol. 2005;207(2):199-206. 81. Cai F, Zhu Q, Miao Y, Shen S, Su X, Shi Y. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res Clin Oncol. 2017;143(1):59-69. 82. Saaber F, Chen Y, Cui T, Yang L, Mireskandari M, Petersen I. Expression of desmogleins 1-3 and their clinical impacts on human lung cancer. Pathol Res Pract. 2015;211(3):208-13. 83. Zhang X, Li W, Hou Y, Niu Z, Zhong Y, Zhang Y, et al. Comparative membrane proteomic analysis between lung adenocarcinoma and normal tissue by iTRAQ labeling mass spectrometry. Am J Transl Res. 2014;6(3):267-80. 84. Li W, Zhang X, Wang W, Sun R, Liu B, Ma Y, et al. Quantitative proteomics analysis of mitochondrial proteins in lung adenocarcinomas and normal lung tissue using iTRAQ and tandem mass spectrometry. Am J Transl Res. 2017;9(9):3918-34. 85. Sun R, Ma C, Wang W, Yang S. Upregulation of desmoglein 2 and its clinical value in lung adenocarcinoma: a comprehensive analysis by multiple bioinformatics methods. PeerJ. 2020;8:e8420. 86. Li S, Qi Z, Li H, Hu J, Wang D, Wang X, et al. Conditionally replicating oncolytic adenoviral vector expressing arresten and tumor necrosis factor-related apoptosis-inducing ligand experimentally suppresses lung carcinoma progression. Mol Med Rep. 2015;12(2):2068-74. 87. Tomono T, Kajita M, Yano K, Ogihara T. Adenovirus vector infection of non-small-cell lung cancer cells is a trigger for multi-drug resistance mediated by P-glycoprotein. Biochem Biophys Res Commun. 2016;476(4):183-7. 88. Qin M, Chen S, Yu T, Escuadro B, Sharma S, Batra RK. Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts. Clin Cancer Res. 2003;9(13):4992-9. 89. Wang H, Beyer I, Persson J, Song H, Li Z, Richter M, et al. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol. 2012;86(11):6286-302. 90. Sakhawat A, Liu Y, Ma L, Muhammad T, Wang S, Zhang L, et al. Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition. J Cancer. 2017;8(8):1425-32. 91. Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Fujimoto M, Tsuruyama T, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer. 2013;81(1):53-9. 92. Hoshi R, Tsuzuku M, Horai T, Ishikawa Y, Satoh Y. Micropapillary clusters in early-stage lung adenocarcinomas: a distinct cytologic sign of significantly poor prognosis. Cancer. 2004;102(2):81-6. 93. Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ, Huang BS, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258(6):1079-86. 94. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992-1001. 95. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653-64. 96. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30(13):1438-46. 97. Cha MJ, Lee HY, Lee KS, Jeong JY, Han J, Shim YM, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014;147(3):921-8 e2. 98. Yanagawa N. The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply. J Thorac Oncol. 2017;12(3):e25-e6. 99. Yanagawa N, Shiono S, Abiko M, Katahira M, Osakabe M, Ogata SY. The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma. J Thorac Oncol. 2016;11(11):1976-83. 100. Sorensen JB, Hirsch FR, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease. Cancer. 1988;62(2):361-7. 101. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29(3):179-88. 102. Shim HS, Lee DH, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med. 2011;135(10):1329-34. 103. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol. 2013;30(3):645. 104. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1):52-61. 105. Hung JJ, Wu YC, Chou TY, Jeng WJ, Yeh YC, Hsu WH. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma. Ann Thorac Surg. 2016;101(4):1346-53. 106. Ma M, She Y, Ren Y, Dai C, Zhang L, Xie H, et al. Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma. J Thorac Dis. 2018;10(9):5384-93. 107. Qian F, Yang W, Wang R, Xu J, Wang S, Zhang Y, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. J Thorac Cardiovasc Surg. 2018;155(3):1227-35 e2. 108. Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, et al. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol. 2015;33(30):3439-46. 109. Nogrady B. How cancer genomics is transforming diagnosis and treatment. Nature. 2020;579(7800):S10-S1. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72816 | - |
dc.description.abstract | 肺癌目前為全球最常被診斷且死亡率最高的癌症。癌症的起因牽涉相當複雜的機轉。過去研究顯示,致癌病毒(Oncovirus)可導致發炎反應相關的訊息傳導路徑及細胞激素分泌產生,因此被認為與腫瘤發生(Tumorigenesis)有關。此外腫瘤的異質性(heterogeneity)於細胞增生(hyperplasia)前即已被偵測到,至於完整的腫瘤發生病生理機轉至今仍尚待釐清。臨床上目前僅能知道,早期診斷合併早期介入治療,為最有效且可降低肺癌死亡率的最好方法。因此肺癌的早期偵測且與預後相關之因子是值得發展的。近半個世紀前的動物實驗研究顯示,特定呼吸道致癌病毒可導致肺腫瘤產生,例如流感病毒感染。然而直到現今,仍未有足夠臨床證據可支持這項假說。為了探討流感病毒感染與日後得到肺癌診斷風險的關聯性,本研究之一,使用台灣癌登資料庫(Taiwan Cancer Registry Database, TCRD)及全民健康保險資料庫(Taiwan’s National Health Insurance Research Database, NHIRD)進行了回溯性分析。收錄的病患皆為年齡大於40 歲。結果顯示,流感病毒感染相較於未感染者,增加了1.09 倍風險得到肺癌,並且與暴露次數呈正相關。近年來關於腫瘤治療的另一重要概念為新生抗原(Neoantigen)。本研究在早期肺腺癌細胞表面上,試圖尋找可能的新生抗原。我們發現, 與腺病毒有關之特定細胞膜載體 (adenovirus-based vectors),除了可能與腫瘤發生有關外,也可作為肺腺癌存活預後之預測因子。這兩個生物標誌(biomarkers) 分別為Coxsackievirus/ adenovirusreceptors (CARs) 及desmoglein-2 (DSG2) 。使用基因功能分類(Gene ontology enrichment analysis)及癌症基因體圖譜(Cancer Genome Atlas)分析後,再將臨床肺癌組織晶片(Tissue microarray, TMA)與免疫組織染色(Immunohistochemical assay,IHC)結果進行大數據分析比對發現,CAR 及 DSG2 基因在早期肺腺癌即共同高度表現,且高表現者預後較差。而肺癌組織晶片進行免疫組織染色後也顯示,CAR及DSG2 在肺腺癌組織中表現量明顯與正常組織不同。CAR 及DSG2,或兩者同時染色強度表現量高者預後較差。除了生物標誌外,組織學亞型過去也被研究與肺癌預後有關,但大多數研究皆為早期肺腺癌患者。本研究根據新分類系統(New International Association for the Study of Lung Cancer Pathology Committee Grading System)針對晚期肺癌病患分析,結果顯示分化不良(poorly differentiated)組別病患無疾病存活期(Progression free survival)預後較差,同樣的結果在顯示在EGFR野生 型接受化學治療的病患。有EGFR 突變之病患並無顯示存活預後統計上差異。因此分化不良相較於中等分化(moderately differentiated) 甚至良好分化(well differentiated)組別,預後是最差的。最後我們強調,於本研究中所有得到的結果,未來在細胞實驗(in vitro)或動物實驗(in vivo)皆須再被驗證。首先要建立流感病毒感染與肺腫瘤產生之明確病生理機轉。另外CAR/DSG2 共同高度表現與臨床存活預後不良有關,未來是否可作為溶瘤病毒(Oncolytic virus)之載體提供基因治療之標的,抑或可當新生抗原運用於免疫治療,也需更多研究釐清。最後則是關於腫瘤的高度異質性在疾病早期即已表現,疾病晚期往往因腫瘤異質性過於複雜,造成臨床治療困難度大幅增加。我們在本研究中建議,晚期肺腺癌病患若被歸類為分化不良EGFR 野生型且接受化學治療者,可考慮合併多種藥物治療,或選擇其他治療方法,以達到更好治療效果,延長病患存活時間。期待未來各項新的研究成果可陸續被驗證,除有助於肺癌早期偵測及診斷外,也可提供更多治療策略並降低死亡率。 | zh_TW |
dc.description.abstract | Lung cancer is a leading cause of life-threatening malignancy worldwide. Cancer initiation involved multiple complex mechanisms. Oncovirus activating associated inflammatory signaling pathway and cytokine had been proposed as one of link to tumorigenesis. In addition, tumor heterogeneity could be detected in the premalignant stage although the pathogenesis remained unclear. Nevertheless, early diagnosis with prompt intervention is crucial to decrease lung-cancer-associated mortality, which would make a tool that could detect, early on, prognostic predictions very valuable. Previous animal studies have shown that certain respiratory oncoviruses can lead to tumorigenesis, especially influenza virus. However, no clinical studies other than animal studies have been conducted to test this hypothesis. To investigate the association between influenza and the risk of lung cancer using the Taiwan Cancer Registry Database (TCRD) and Taiwan’s National Health Insurance Research Database (NHIRD), we conducted a cohort study cohort consisting of patients aged 40 years or above. Influenza was associated with a 1.09- fold increased risk of lung cancer. Exposure to influenza was associated with an increased risk of lung cancer and the risk increased with cumulative exposure to influenza. In addition, cancer neoantigens presenting on the surface of individual cancer cells are fully cancer-specific and important targets for checkpoint blockade therapy. We thus attempt to discover novel neoantigens. There are two adenovirus-based vectors in the cell membrane in our study were proposed as in association with lung epithelial cell tumorigenesis and exert markers in predicting survival outcome in lung adenocarcinoma (LUAD). The two biomarkers were Coxsackievirus/adenovirus receptors (CARs) and desmoglein-2 (DSG2). After gene ontology enrichment analysis and survival analysis extracted from The Cancer Genome Atlas (TCGA), we then investigate a tissue microarray (TMA) and staining by immunohistochemical (IHC) assay then calculating by computer counting software to determine the H-score of the immune intensity. CAR and DSG2 genes are highly co-expressed in early stage LUAD and associated with significantly poorer survival. TMA also showed that CAR/DSG2 expressions were altered in lung cancer tissue. CAR, DSG2, or a co-expression of CAR/DSG2 was associated with poorer overall survival. The co-expression biomarkers predicted a worse overall survival in LUAD. Other than biomarkers, histologic subtypes also participate in prognostic relevance in lung cancer and were in our study interest. Despite important role of histologic classification in prediction outcome in early stage LUAD. We apply new International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System among advanced stage (stages IIIA, IIIB and IV) LUAD patients, which indicate that the poorly differentiated group had a poorer prognosis in progression free survival (PFS), as did patients with wild-type EGFR who were treated with chemotherapy. There was no survival difference found among EGFR mutation patients. Patients with poorly differentiated LUAD likewise had worse survival, especially compared to those with moderately differentiated LUAD. Our findings highlight that more in vitro and in vivo investigations are warranted to validate and to better understand the mechanisms of potential association between influenza virus infection and lung cancer. Further researches are also necessary to confirm the clinical usage concept of tumor gene delivery therapy based on the concept that CAR/DSG2 co-expression in predicting prognosis and postulated to be efficiency of gene therapy using oncolytic adenoviruses for treating lung cancer, or as a neoantigen for immunotherapy. Finally, regardless of tumor heterogeneity in any stage, we emphasize that the therapeutic regimen should be adjusted for wild-type EGFR patients with poorly differentiated LUAD treated with chemotherapy for better outcomes according to new grading system classification. We look forward upcoming verified investigation results both facilitate earlier diagnosis of lung cancer and new treatment strategies for decreasing cancer related mortality. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:07:01Z (GMT). No. of bitstreams: 1 U0001-0501202111430200.pdf: 4957140 bytes, checksum: fa638f5edc1712711212bf9afa468376 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 目 錄 口試委員會審定書.....................................................................I 謝誌.............................................................................. II 中文摘要 ............................................................................... IV Abstract .................................................................................. VI 1. INTRODUCTION ................................................................................... 1 1.1 Lung Cancer ....................................................................................1 1.2 Oncovirus: potential role of influenza virus .................................................. 2 1.3 Epithelial viral receptor .................................................................................. 2 1.4 Prognostic relevance of lung adenocarcinoma biomarkers expression ....... 3 1.5 Prognostic relevance of lung adenocarcinoma histologic classification ....... 4 1.6 Study specific aims ................................................................................... 6 2. MATERIALS AND METHODS .............................................................................. 7 2.1 Association between influenza virus infection and the risk of lung cancer . 7 2.1.1 Study design and data source .............................................................. 7 2.1.2 Ethical statement .................................................................................. 7 2.1.3 Study population .................................................................................. 8 2.1.4 Cases and controls ................................................................................ 8 2.1.5 Exposure to influenza ........................................................................... 9 2.1.6 Statistical and subgroup analyses ...................................................... 10 2.2 Potential roles of DSG2 and CAR for lung cancer and the correlation between their high expression and survival ...................................................... 11 2.2.1 Data from Online Databases .............................................................. 11 2.2.2 Patients and Tissues ........................................................................... 13 2.2.3. Statistical Analysis.......................................................................... 14 2.2.4. Immunohistochemical Staining (IHC) ............................................. 14 2.2.5. Statistics .................................................................................. 16 2.3 Prognostic relevance of the new grading system in advanced lung adenocarcinoma .................................................................................. 17 2.3.1. Participants .................................................................................. 17 2.3.2. Mutational Analysis .......................................................................... 18 2.3.3. Statistical Analysis......................................................................... 19 doi:10.6342/NTU202100015 3. RESULTS ...................................................................................20 3.1 Influenza exposure and the risk of lung cancer .......................................... 20 3.2 Association between Clinical Variables and CAR/DSG2 Expression ........ 22 3.2.1 Correlations between CAR/DSG2 Protein Expression, Proliferation, Apoptosis, Angiogenesis, and EMT............................................................ 23 3.2.2 Survival Analysis ................................................................................ 24 3.3 Clinical relevance by IASLC pathology committee’s new grading system 25 3.3.1 Clinicopathological Factors ............................................................... 25 3.3.2 EGFR Wild-Type and EGFR Mutations and First-Line Treatment ...................................................................................26 3.3.3 Survival Analysis ................................................................................ 26 4. DISCUSSION ................................................................................. 28 4.1. Association between the risk of lung cancer and influenza ....................... 28 4.2. Clinical relevance of co-Expression of Coxsackievirus/Adenovirus Receptors and Desmoglein 2 in Lung Adenocarcinoma ................................ 32 4.3. New IASLC Pathology Committee Grading System for the prognostic outcome of advanced lung adenocarcinoma ...................................................... 37 5. CONCLUSION .................................................................................. 42 6. FIGURES .................................................................................. 44 7. TABLES .................................................................................. 65 8. REFERENCES ...................................................................................84 9. PUBLICATION .................................................................................. 93 | |
dc.language.iso | zh-TW | |
dc.title | 肺癌起始機制之監測及組織學和生物標誌表達的預後相關性 | zh_TW |
dc.title | Surveillance for the mechanism of lung cancer initiation and prognostic relevance of histologic and biomarkers expression | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 黃彥華(Yen-Hua Huang),李興中(Hsin-Chung Lee),林琬琬(Wan-Wan Lin),何肇基(CHAO-CHI HO) | |
dc.subject.keyword | 肺癌,致癌病毒,流感病毒,新生抗原,生物標誌,溶瘤病毒,組織亞型, | zh_TW |
dc.subject.keyword | Lung cancer,adenocarcinoma,oncovirus,influenza virus,biomarker,neoantigen,histology subtype, | en |
dc.relation.page | 93 | |
dc.identifier.doi | 10.6342/NTU202100015 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2021-01-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0501202111430200.pdf 目前未授權公開取用 | 4.84 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。